Fructose and fructose kinase in cancer and other pathologies

Hongfei Jiang; Qian Lin; Leina Ma; Shudi Luo; Xiaoming Jiang; Jing Fang; Zhimin Lu

doi:10.1016/j.jgg.2021.06.006

Volume 48 Issue 7

Jul. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Genetics and Genomics > 2021 > 48(7): 531-539

PDF( 999 KB)

Fructose and fructose kinase in cancer and other pathologies

doi: 10.1016/j.jgg.2021.06.006

a Cancer Institute of The Affiliated Hospital of Qingdao University and Qingdao Cancer Institute, Qingdao 266061, China;
b Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou 310029, China;
c Zhejiang University Cancer Center, Hangzhou 310029, China

Funds:

82073061, J.F.

This study was supported by grants from the Ministry of Science and Technology of the People's Republic of China (2020YFA0803300 to Z.L., J.F.), the National Natural Science Foundation of China (82030074, Z.L.

81672926, L.M.), the Zhejiang Natural Science Foundation-Key Project (LD21H160003, Z.L.), the Zhejiang University Research Fund (188020*194221901/029, Z.L.), and the Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang (2019R01001, Z.L.). Z.L. is the Kuancheng Wang Distinguished Chair.

Received Date: 2021-04-02
Accepted Date: 2021-06-22
Rev Recd Date: 2021-06-22
Publish Date: 2021-07-20

Abstract

Abstract

Fructose metabolism and fructose kinase KHK–C/A are key factors in the development of lipid oversynthesis-promoted metabolic disorders and cancer. Here, we summarize and discuss the current knowledge about the specific features of fructose metabolism and the distinct roles of KHK–C and KHK–A in metabolic liver diseases and their relevant metabolic disorders and cancer, and we highlight the specific protein kinase activity of KHK–A in tumor development. In addition, different approaches that have been used to inhibit KHK and the exploration of KHK inhibitors in clinical treatment are introduced.
- Fructose,
- Glucose,
- KHK–C,
- KHK-A,
- Cancer,
- NAFLD,
- NASH,
- Metabolic disorders

FullText(HTML)

References(91)

References

Ahmed, N., Furth, A.J., 1992. Failure of common glycation assays to detect glycation by fructose. Clin. Chem. 38, 1301-1303.

Alwahsh, S.M., Gebhardt, R., 2017. Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD). Arch. Toxicol. 91, 1545-1563.

Andrews, Z.B., 2011. The extra-hypothalamic actions of ghrelin on neuronal function. Trends Neurosci. 34, 31-40.

Banks, W.A., Coon, A.B., Robinson, S.M., Moinuddin, A., Shultz, J.M., Nakaoke, R., Morley, J.E., 2004. Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes 53, 1253-1260.

Bian, X., Liu, R., Meng, Y., Xing, D., Xu, D., Lu, Z., 2021. Lipid metabolism and cancer. J. Exp. Med. 218, e20201606.

Bizeau, M.E., Pagliassotti, M.J., 2005. Hepatic adaptations to sucrose and fructose. Metabolism 54, 1189-1201.

Bose, T., Chakraborti, A.S., 2008. Fructose-induced structural and functional modifications of hemoglobin:implication for oxidative stress in diabetes mellitus. Biochim. Biophys. Acta 1780, 800-808.

Brennan, A.M., Mantzoros, C.S., 2006. Drug insight:the role of leptin in human physiology and pathophysiology-emerging clinical applications. Nat. Clin. Pract. Endocrinol. Metabol. 2, 318-327.

Bu, P., Chen, K.Y., Xiang, K., Johnson, C., Crown, S.B., Rakhilin, N., Ai, Y., Wang, L., Xi, R., Astapova, I., et al., 2018. Aldolase B-mediated fructose metabolism drives metabolic reprogramming of colon cancer liver metastasis. Cell Metabol. 27, 1249-1262. e4.

Bunn, H.F., Higgins, P.J., 1981. Reaction of monosaccharides with proteins:possible evolutionary significance. Science 213, 222-224.

Cave, M., Deaciuc, I., Mendez, C., Song, Z., Joshi-Barve, S., Barve, S., McClain, C., 2007. Nonalcoholic fatty liver disease:predisposing factors and the role of nutrition. J. Nutr. Biochem. 18, 184-195.

Cha, S.H., Wolfgang, M., Tokutake, Y., Chohnan, S., Lane, M.D., 2008. Differential effects of central fructose and glucose on hypothalamic malonyl-Coa and food intake. Proc. Natl. Acad. Sci. U. S. A. 105, 16871-16875.

Chen, W.L., Jin, X., Wang, M., Liu, D., Luo, Q., Tian, H., Cai, L., Meng, L., Bi, R., Wang, L., et al., 2020. GLUT5-mediated fructose utilization drives lung cancer growth by stimulating fatty acid synthesis and AMPK/mTORC1 signaling. JCI Insight 5, e131596.

Chen, W.L., Wang, Y.Y., Zhao, A., Xia, L., Xie, G., Su, M., Zhao, L., Liu, J., Qu, C., Wei, R., et al., 2016. Enhanced fructose utilization mediated by SLC2A5 is a unique metabolic feature of acute myeloid leukemia with therapeutic potential. Canc. Cell 30, 779-791.

Cook, S., Hugli, O., Egli, M., Vollenweider, P., Burcelin, R., Nicod, P., Thorens, B., Scherrer, U., 2003. Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. Swiss Med. Wkly. 133, 360-363.

Dewdney, B., Alanazy, M., Gillman, R., Walker, S., Wankell, M., Qiao, L., George, J., Roberts, A., Hebbard, L., 2020. The effects of fructose and metabolic inhibition on hepatocellular carcinoma. Sci. Rep. 10, 16769.

Dhingra, R., Sullivan, L., Jacques, P.F., Wang, T.J., Fox, C.S., Meigs, J.B., D'Agostino, R.B., Gaziano, J.M., Vasan, R.S., 2007. Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation 116, 480-488.

Diggle, C.P., Shires, M., Leitch, D., Brooke, D., Carr, I.M., Markham, A.F., Hayward, B.E., Asipu, A., Bonthron, D.T., 2009. Ketohexokinase:expression and localization of the principal fructose-metabolizing enzyme. J. Histochem. Cytochem. 57, 763-774.

Diggle, C.P., Shires, M., McRae, C., Crellin, D., Fisher, J., Carr, I.M., Markham, A.F., Hayward, B.E., Asipu, A., Bonthron, D.T., 2010. Both isoforms of ketohexokinase are dispensable for normal growth and development. Physiol. Genom. 42A, 235-243.

Douard, V., Ferraris, R.P., 2008. Regulation of the fructose transporter GLUT5 in health and disease. Am. J. Physiol. Endocrinol. Metab. 295, E227-E237.

Du, L., Heaney, A.P., 2012. Regulation of adipose differentiation by fructose and GLUT5. Mol. Endocrinol. 26, 1773-1782.

Eid, B.G., Neamatallah, T., Hanafy, A., El-Bassossy, H.M., Aldawsari, H.M., Vemuri, K., Makriyannis, A., 2020. Effects of the CB1 receptor antagonists AM6545 and AM4113 on insulin resistance in a high-fructose high-salt rat model of metabolic syndrome. Medicina (Kaunas) 56, 573.

Feig, D.I., Soletsky, B., Johnson, R.J., 2008. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension:a randomized trial. J. Am. Med. Assoc. 300, 924-932.

Futatsugi, K., Smith, A.C., Tu, M., Raymer, B., Ahn, K., Coffey, S.B., Dowling, M.S., Fernando, D.P., Gutierrez, J.A., Huard, K., et al., 2020. Discovery of PF-06835919:a potent inhibitor of ketohexokinase (KHK) for the treatment of metabolic disorders driven by the overconsumption of fructose. J. Med. Chem. 63, 13546-13560.

Girniene, J., Tatibouet, A., Sackus, A., Yang, J., Holman, G.D., Rollin, P., 2003. Inhibition of the D-fructose transporter protein glut5 by fused-ring glyco-1,3-oxazolidin-2-thiones and -oxazolidin-2-ones. Carbohydr. Res. 338, 711-719.

Goncalves, M.D., Lu, C., Tutnauer, J., Hartman, T.E., Hwang, S.K., Murphy, C.J., Pauli, C., Morris, R., Taylor, S., Bosch, K., et al., 2019. High-fructose corn syrup enhances intestinal tumor growth in mice. Science 363, 1345-1349.

Gutierrez, J.A., Liu, W., Perez, S., Xing, G., Sonnenberg, G., Kou, K., Blatnik, M., Allen, R., Weng, Y., Vera, N.B., et al., 2021. Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction. Mol. Metab. 48, 101196.

Havel, P.J., 2005. Dietary fructose:implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. Nutr. Rev. 63, 133-157.

Hayward, B.E., Bonthron, D.T., 1998. Structure and alternative splicing of the ketohexokinase gene. Eur. J. Biochem. 257, 85-91.

Huard, K., Ahn, K., Amor, P., Beebe, D.A., Borzilleri, K.A., Chrunyk, B.A., Coffey, S.B., Cong, Y., Conn, E.L., Culp, J.S., et al., 2017. Discovery of fragment-derived small molecules for in vivo inhibition of ketohexokinase (KHK). J. Med. Chem. 60, 7835-7849.

Ishimoto, T., Lanaspa, M.A., Le, M.T., Garcia, G.E., Diggle, C.P., Maclean, P.S., Jackman, M.R., Asipu, A., Roncal-Jimenez, C.A., Kosugi, T., et al., 2012. Opposing effects of fructokinase C and A isoforms on fructose-induced metabolic syndrome in mice. Proc. Natl. Acad. Sci. U. S. A. 109, 4320-4325.

Ishimoto, T., Lanaspa, M.A., Rivard, C.J., Roncal-Jimenez, C.A., Orlicky, D.J., Cicerchi, C., McMahan, R.H., Abdelmalek, M.F., Rosen, H.R., Jackman, M.R., et al., 2013. High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology 58, 1632-1643.

Jaiswal, N., Agrawal, S., Agrawal, A., 2019. High fructose-induced metabolic changes enhance inflammation in human dendritic cells. Clin. Exp. Immunol. 197, 237-249.

Jeong, S., Savino, A.M., Chirayil, R., Barin, E., Cheng, Y., Park, S.M., Schurer, A., Mullarky, E., Cantley, L.C., Kharas, M.G., et al., 2021. High fructose drives the serine synthesis pathway in acute myeloid leukemic cells. Cell Metabol. 33, 145-159. e6.

Jiang, H., Zhu, L., Xu, D., Lu, Z., 2020. A newly discovered role of metabolic enzyme PCK1 as a protein kinase to promote cancer lipogenesis. Cancer Commun. 40, 389-394.

Jiang, Y., Li, X., Yang, W., Hawke, D.H., Zheng, Y., Xia, Y., Aldape, K., Wei, C., Guo, F., Chen, Y., et al., 2014a. Pkm2 regulates chromosome segregation and mitosis progression of tumor cells. Mol. Cell 53, 75-87.

Jiang, Y., Wang, Y., Wang, T., Hawke, D.H., Zheng, Y., Li, X., Zhou, Q., Majumder, S., Bi, E., Liu, D.X., et al., 2014b. PKM2 phosphorylates MLC2 and regulates cytokinesis of tumour cells. Nat. Commun. 5, 5566.

Jin, X., Liang, Y., Liu, D., Luo, Q., Cai, L., Wu, J., Jia, L., Chen, W.L., 2019. An essential role for GLUT5-mediated fructose utilization in exacerbating the malignancy of clear cell renal cell carcinoma. Cell Biol. Toxicol. 35, 471-483.

Johnson, R.J., Segal, M.S., Sautin, Y., Nakagawa, T., Feig, D.I., Kang, D.H., Gersch, M.S., Benner, S., Sanchez-Lozada, L.G., 2007. Potential role of sugar(fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am. J. Clin. Nutr. 86, 899-906.

Jones, N., Blagih, J., Zani, F., Rees, A., Hill, D.G., Jenkins, B.J., Bull, C.J., Moreira, D., Bantan, A.I.M., Cronin, J.G., et al., 2021. Fructose reprogrammes glutaminedependent oxidative metabolism to support LPS-induced inflammation. Nat. Commun. 12, 1209.

Kim, J., Kang, J., Kang, Y.L., Woo, J., Kim, Y., Huh, J., Park, J.W., 2020. Ketohexokinase-A acts as a nuclear protein kinase that mediates fructose-induced metastasis in breast cancer. Nat. Commun. 11, 5436.

Kim, M., Astapova, I.I., Flier, S.N., Hannou, S.A., Doridot, L., Sargsyan, A., Kou, H.H., Fowler, A.J., Liang, G., Herman, M.A., 2017. Intestinal, but not hepatic, chrebp is required for fructose tolerance. JCI Insight 2, e96703.

Kim, M.S., Krawczyk, S.A., Doridot, L., Fowler, A.J., Wang, J.X., Trauger, S.A., Noh, H.L., Kang, H.J., Meissen, J.K., Blatnik, M., et al., 2016. ChREBP regulates fructose-induced glucose production independently of insulin signaling. J. Clin. Invest. 126, 4372-4386.

Kisioglu, B., Nergiz-Unal, R., 2020. Potential effect of maternal dietary sucrose or fructose syrup on CD36, leptin, and ghrelin-mediated fetal programming of obesity. Nutr. Neurosci. 23, 210-220.

Krause, N., Wegner, A., 2020. Fructose metabolism in cancer. Cells 9, 2635.

Kuehm, L.M., Khojandi, N., Piening, A., Klevorn, L.E., Geraud, S.C., McLaughlin, N.R., Griffett, K., Burris, T.P., Pyles, K.D., Nelson, A.M., et al., 2021. Fructose promotes cytoprotection in melanoma tumors and resistance to immunotherapy. Cancer Immunol. Res. 9, 227-238.

Lanaspa, M.A., Ishimoto, T., Li, N., Cicerchi, C., Orlicky, D.J., Ruzycki, P., Rivard, C., Inaba, S., Roncal-Jimenez, C.A., Bales, E.S., et al., 2013. Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome. Nat. Commun. 4, 2434.

Li, X., Egervari, G., Wang, Y., Berger, S.L., Lu, Z., 2018. Regulation of chromatin and gene expression by metabolic enzymes and metabolites. Nat. Rev. Mol. Cell Biol. 19, 563-578.

Li, X., Jiang, Y., Meisenhelder, J., Yang, W., Hawke, D.H., Zheng, Y., Xia, Y., Aldape, K., He, J., Hunter, T., et al., 2016a. Mitochondria-translocated PGK1 functions as a protein kinase to coordinate glycolysis and the TCA cycle in tumorigenesis. Mol. Cell 61, 705-719.

Li, X., Qian, X., Lu, Z., 2016b. Fructokinase a acts as a protein kinase to promote nucleotide synthesis. Cell Cycle 15, 2689-2690.

Li, X., Qian, X., Peng, L.X., Jiang, Y., Hawke, D.H., Zheng, Y., Xia, Y., Lee, J.H., Cote, G., Wang, H., et al., 2016c. A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation. Nat. Cell Biol. 18, 561-571.

Li, X., Zheng, Y., Lu, Z., 2016d. PGK1 is a new member of the protein kinome. Cell Cycle 15, 1803-1804.

Lim, J.S., Mietus-Snyder, M., Valente, A., Schwarz, J.M., Lustig, R.H., 2010. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat. Rev. Gastroenterol. Hepatol. 7, 251-264.

Lyssiotis, C.A., Cantley, L.C., 2013. Metabolic syndrome:F stands for fructose and fat. Nature 502, 181-182.

Manolescu, A.R., Witkowska, K., Kinnaird, A., Cessford, T., Cheeseman, C., 2007. Facilitated hexose transporters:new perspectives on form and function. Physiology 22, 234-240.

Maryanoff, B.E., O'Neill, J.C., McComsey, D.F., Yabut, S.C., Luci, D.K., Gibbs, A.C., Connelly, M.A., 2012. Pyrimidinopyrimidine inhibitors of ketohexokinase:exploring the ring C2 group that interacts with Asp-27B in the ligand binding pocket. Bioorg. Med. Chem. Lett. 22, 5326-5329.

Maryanoff, B.E., O'Neill, J.C., McComsey, D.F., Yabut, S.C., Luci, D.K., Jordan Jr., A.D., Masucci, J.A., Jones, W.J., Abad, M.C., Gibbs, A.C., et al., 2011. Inhibitors of ketohexokinase:discovery of pyrimidinopyrimidines with specific substitution that complements the ATP-binding site. ACS Med. Chem. Lett. 2, 538-543.

Mirtschink, P., Krishnan, J., Grimm, F., Sarre, A., Horl, M., Kayikci, M., Fankhauser, N., Christinat, Y., Cortijo, C., Feehan, O., et al., 2015. Hif-driven SF3B1 induces KHKeC to enforce fructolysis and heart disease. Nature 522, 444-449.

Mracek, T., Drahota, Z., Houstek, J., 2013. The function and the role of the mitochondrial glycerol-3-phosphate dehydrogenase in mammalian tissues. Biochim. Biophys. Acta 1827, 401-410.

Nagai, R., Ikeda, K., Higashi, T., Sano, H., Jinnouchi, Y., Araki, T., Horiuchi, S., 1997. Hydroxyl radical mediates N epsilon-(carboxymethyl)lysine formation from Amadori product. Biochem. Biophys. Res. Commun. 234, 167-172.

Nagai, Y., Yonemitsu, S., Erion, D.M., Iwasaki, T., Stark, R., Weismann, D., Dong, J., Zhang, D., Jurczak, M.J., Loffler, M.G., et al., 2009. The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. Cell Metabol. 9, 252-264.

Nakagawa, T., Lanaspa, M.A., Millan, I.S., Fini, M., Rivard, C.J., SanchezLozada, L.G., Andres-Hernando, A., Tolan, D.R., Johnson, R.J., 2020. Fructose contributes to the Warburg effect for cancer growth. Cancer Metabol. 8, 16.

Ochoa, M., Lalles, J.P., Malbert, C.H., Val-Laillet, D., 2015. Dietary sugars:their detection by the gut-brain axis and their peripheral and central effects in health and diseases. Eur. J. Nutr. 54, 1-24.

Oh, A.R., Sohn, S., Lee, J., Park, J.M., Nam, K.T., Hahm, K.B., Kim, Y.B., Lee, H.J., Cha, J.Y., 2018. ChREBP deficiency leads to diarrhea-predominant irritable bowel syndrome. Metabolism 85, 286-297.

Ozawa, T., Maehara, N., Kai, T., Arai, S., Miyazaki, T., 2016. Dietary fructose-induced hepatocellular carcinoma development manifested in mice lacking apoptosis inhibitor of macrophage (AIM). Gene Cell. 21, 1320-1332.

Perez-Pozo, S.E., Schold, J., Nakagawa, T., Sanchez-Lozada, L.G., Johnson, R.J., Lillo, J.L., 2010. Excessive fructose intake induces the features of metabolic syndrome in healthy adult men:role of uric acid in the hypertensive response. Int. J. Obes. 34, 454-461.

Perheentupa, J., Raivio, K., 1967. Fructose-induced hyperuricaemia. Lancet 2, 528-531.

Qian, X., Li, X., Cai, Q., Zhang, C., Yu, Q., Jiang, Y., Lee, J.H., Hawke, D., Wang, Y., Xia, Y., et al., 2017a. Phosphoglycerate kinase 1 phosphorylates Beclin1 to induce autophagy. Mol. Cell 65, 917-931 e6.

Qian, X., Li, X., Lu, Z., 2017b. Protein kinase activity of the glycolytic enzyme PGK1 regulates autophagy to promote tumorigenesis. Autophagy 13, 1246-1247.

Qian, X., Li, X., Tan, L., Lee, J.H., Xia, Y., Cai, Q., Zheng, Y., Wang, H., Lorenzi, P.L., Lu, Z., 2018. Conversion of prps hexamer to monomer by AMPK-mediated phosphorylation inhibits nucleotide synthesis in response to energy stress. Cancer Discov. 8, 94-107.

Schalkwijk, C.G., Stehouwer, C.D., van Hinsbergh, V.W., 2004. Fructose-mediated non-enzymatic glycation:sweet coupling or bad modification. Diabetes Metab. Res. Rev. 20, 369-382.

Simiand, J., Keane, M., Keane, P.E., Soubrie, P., 1998. Sr 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav. Pharmacol. 9, 179-181.

Softic, S., Meyer, J.G., Wang, G.X., Gupta, M.K., Batista, T.M., Lauritzen, H., Fujisaka, S., Serra, D., Herrero, L., Willoughby, J., et al., 2019. Dietary sugars alter hepatic fatty acid oxidation via transcriptional and post-translational modifications of mitochondrial proteins. Cell Metabol. 30, 735-753 e4.

Stanhope, K.L., Schwarz, J.M., Keim, N.L., Griffen, S.C., Bremer, A.A., Graham, J.L., Hatcher, B., Cox, C.L., Dyachenko, A., Zhang, W., et al., 2009. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J. Clin. Invest. 119, 1322-1334.

Tao, Q.F., Yuan, S.X., Yang, F., Yang, S., Yang, Y., Yuan, J.H., Wang, Z.G., Xu, Q.G., Lin, K.Y., Cai, J., et al., 2015. Aldolase B inhibits metastasis through ten-eleven translocation 1 and serves as a prognostic biomarker in hepatocellular carcinoma. Mol. Cancer 14, 170.

Tran, C., 2017. Inborn errors of fructose metabolism. What can we learn from them? Nutrients 9, 356.

Wang, H., Sun, R.Q., Zeng, X.Y., Zhou, X., Li, S., Jo, E., Molero, J.C., Ye, J.M., 2015. Restoration of autophagy alleviates hepatic ER stress and impaired insulin signalling transduction in high fructose-fed male mice. Endocrinology 156, 169-181.

Wang, Y., Xia, Y., Lu, Z., 2018. Metabolic features of cancer cells. Cancer Commun. 38, 65.

Wei, Y., Wang, D., Topczewski, F., Pagliassotti, M.J., 2007. Fructose-mediated stress signaling in the liver:implications for hepatic insulin resistance. J. Nutr. Biochem. 18, 1-9.

Wren, A.M., Seal, L.J., Cohen, M.A., Brynes, A.E., Frost, G.S., Murphy, K.G., Dhillo, W.S., Ghatei, M.A., Bloom, S.R., 2001a. Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab. 86, 5992.

Wren, A.M., Small, C.J., Abbott, C.R., Dhillo, W.S., Seal, L.J., Cohen, M.A., Batterham, R.L., Taheri, S., Stanley, S.A., Ghatei, M.A., et al., 2001b. Ghrelin causes hyperphagia and obesity in rats. Diabetes 50, 2540-2547.

Xu, D., Li, X., Shao, F., Lv, G., Lv, H., Lee, J.H., Qian, X., Wang, Z., Xia, Y., Du, L., et al., 2019. The protein kinase activity of fructokinase a specifies the antioxidant responses of tumor cells by phosphorylating p62. Sci. Adv. 5, eaav4570.

Xu, D., Wang, Z., Xia, Y., Shao, F., Xia, W., Wei, Y., Li, X., Qian, X., Lee, J.H., Du, L., et al., 2020. The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis. Nature 580, 530-535.

Yang, J., Dowden, J., Tatibouet, A., Hatanaka, Y., Holman, G.D., 2002. Development of high-affinity ligands and photoaffinity labels for the D-fructose transporter GLUT5. Biochem. J. 367, 533-539.

Yang, W., Lu, Z., 2013. Nuclear PKM2 regulates the warburg effect. Cell Cycle 12, 3154-3158.

Yang, W., Xia, Y., Hawke, D., Li, X., Liang, J., Xing, D., Aldape, K., Hunter, T., Alfred Yung, W.K., Lu, Z., 2012. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 150, 685-696.

Yang, X., Shao, F., Shi, S., Feng, X., Wang, W., Wang, Y., Guo, W., Wang, J., Gao, S., Gao, Y., et al., 2019. Prognostic impact of metabolism reprogramming markers acetyl-CoA synthetase 2 phosphorylation and ketohexokinase-A expression in non-small-cell lung carcinoma. Front. Oncol. 9, 1123.

Zachari, M., Ganley, I.G., 2017. The mammalian ULK1 complex and autophagy initiation. Essays Biochem. 61, 585-596.

Zhang, X., Song, F., Kuo, G.H., Xiang, A., Gibbs, A.C., Abad, M.C., Sun, W., Kuo, L.C., Sui, Z., 2011. Optimization of a pyrazole hit from FBDD into a novel series of indazoles as ketohexokinase inhibitors. Bioorg. Med. Chem. Lett. 21, 4762-4767.

Zhang, X.Q., Xu, C.F., Yu, C.H., Chen, W.X., Li, Y.M., 2014. Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease. World J. Gastroenterol. 20, 1768-1776.

Zhao, S., Jang, C., Liu, J., Uehara, K., Gilbert, M., Izzo, L., Zeng, X., Trefely, S., Fernandez, S., Carrer, A., et al., 2020. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. Nature 579, 586-591.

Relative Articles

Supplements(0)

Cited By

Proportional views